Elevance Health, Inc. (ELV)
Elevance Health: Making The Bull Case For Ongoing Recovery (Rating Upgrade)
Elevance Health, Inc. has rebounded ~34% from its March lows, supported by sector recovery and improved Q1 2026 results. Q1 2026 saw ELV revenue up 1.5% to $49.5bn, adjusted EPS up 5.1% to $12.58, and a benefit expense ratio improvement to 86.8%. ELV raised 2026 adjusted EPS guidance to at least $26.75 and expects a return to 12% adjusted EPS growth in 2027.
Elevance Health (ELV) Up 12.6% Since Last Earnings Report: Can It Continue?
Elevance Health (ELV) reported earnings 30 days ago. What's next for the stock?
Elevance Health, Inc. (ELV) Shareholder/Analyst Call Prepared Remarks Transcript
Elevance Health, Inc. (ELV) Shareholder/Analyst Call Prepared Remarks Transcript
ELV Beats Q1 Earnings Estimates on Rising Net Investment Income
Elevance Health beats Q1 EPS estimates as net investment income jumps 29.7%, offsetting membership decline and higher expenses.
Elevance Health, Inc. (ELV) Q1 2026 Earnings Call Transcript
Elevance Health, Inc. (ELV) Q1 2026 Earnings Call Transcript
Here's What Key Metrics Tell Us About Elevance Health (ELV) Q1 Earnings
While the top- and bottom-line numbers for Elevance Health (ELV) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Elevance Health (ELV) Surpasses Q1 Earnings and Revenue Estimates
Elevance Health (ELV) came out with quarterly earnings of $12.58 per share, beating the Zacks Consensus Estimate of $10.68 per share. This compares to earnings of $11.97 per share a year ago.
Elevance Health Profits Eclipse $1.7 Billion Despite Elevated Costs
Elevance Health Wednesday reported nearly $1.8 billion in first quarter net income as costs continued to be a drag on earnings of the nation's second-largest health insurance company.
Elevance raises annual profit forecast betting on cost control
Elevance Health raised its annual profit forecast on Wednesday, as it looks to keep medical costs in check.
Stay Ahead of the Game With Elevance Health (ELV) Q1 Earnings: Wall Street's Insights on Key Metrics
Beyond analysts' top-and-bottom-line estimates for Elevance Health (ELV), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Will Health Benefits Weakness Drag Elevance's Q1 Earnings?
ELV heads into its April 22 Q1 report with EPS likely down 11.4% as Health Benefits operating income is projected to plunge 13.7% year over year.
Elevance Health: New Medicare Payment Rate A Gift, And The Chart Looks Good
Elevance Health, Inc. is rated a Buy, with valuation now compelling after significant underperformance versus the S&P 500. Despite fundamental headwinds—declining membership, higher benefit expense ratios, and muted guidance—ELV targets 12% annual adjusted EPS growth long-term. Shares are deeply discounted, trading below fair value on both P/E and price-to-sales metrics, with technicals suggesting a potential bottom.
